5 天之前 · GRAIL is a healthcare company innovating to solve healthcare’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it may be more treatable and potentially curable.

MENLO PARK, Calif. , Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter 2024 following the …

5 天之前 · GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring.

2025年1月13日 · GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring.

GRAIL uses advanced machine learning algorithms and pattern recognition to “read” methylation patterns. Using these two principles, the Galleri test has three scientific steps: Extract and sequence the DNA fragments from the blood to “read” the methylation patterns (assay)

2024年7月15日 · GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring.

Everything we do is guided by our mission to detect cancer early, when it can be cured. We have a group of people at GRAIL whose talent, commitment, and creativity are unmatched. And as we grow, we’re looking for people who will increase the impact we can make on the world.

5 天之前 · GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring.

GRAIL Updates; The Cancer SIGNAL Podcast; Media Resources; Investor Relations; Galleri Test; Careers; Get in touch; Search Our clinical study program. We are committed to the utmost scientific rigor and have enrolled over 300,000 participants in a clinical study program to demonstrate broad applicability of our multi-cancer early detection ...

To pursue a mission like GRAIL’s, it takes all of us—a unified collective of courageous, adaptable, and open-minded big thinkers dedicated to creating a better world. Our leadership team strives to push the boundaries of what is possible to achieve our bold mission.